Objective: The threat of non-communicable diseases (''NCDs'') is increasingly becoming a global health crisis and are pervasive in high, middle, and low-income populations resulting in an estimated 36 million deaths per year. There is a need to assess intellectual property rights (''IPRs'') that may impede generic production and availability and affordability to essential NCD medicines.
Introduction
Almost two-thirds of the 57 million global deaths occurring in 2008 were due to non-communicable diseases (''NCDs''), primarily: cardiovascular disease, diabetes, cancer and chronic respiratory disease, which are now the leading causes of deaths globally. [1, 2] In fact, almost 80% of NCD-related deaths occurs in low-and middle-income countries (''LMICs''), representing the most frequent causes of mortality on most continents, with the exception of Africa. [1, 3] Around the world, annual NCD mortality is projected to continue to rise, especially in LMICs, which are expected to experience the greatest increase in prevalence. [1, 4] Indeed, ,80% of cardiovascular and diabetes mortality, nearly 90% of mortality from chronic obstructive pulmonary disease, and greater than two-thirds of cancer mortality occur in LMICs, though in low-income countries infectious diseases remain the major causes of mortality. [1, 2, 5] This rise in NCD prevalence, coupled with high out-of-pocket expenditures for medicines in LMICs, highlights a growing and disproportionate impact in resource-poor populations and the need to examine potential barriers to medication access. [1, 3, 6, 7] .
With this epidemiological shift from communicable to NCDs [1, 4, 8] , the international community is paying greater attention to this global health threat, with the UN General Assembly convened a high-level meeting in September 2011 with participating Member States on the prevention and control of NCDs. [9] While prevention is a predominant public health strategy [1, 10] , availability and affordability to life-saving medications is also critical. This includes assessment of availability of generic essential medicines, whose presence generally results in greater availability of cheaper medications in comparison to innovator products that are often subject to IPRs. [6, 8] Indeed, studies have reported that LMICs can experience over 300% in pricing differentials between originator and lowest-price generics in the private sector. [7] In the case of HIV/AIDS, patent protection and related delayed market production of generic antiretroviral therapy (''ARVs'') led to pressure from civil society, eventual generic production and price negotiation, and the subsequent dramatic lowering of the cost of ARVs for resource-poor settings. [11] .
Yet, comprehensive patent and exclusivity analysis on essential NCD medicines has not been adequately assessed. Previous studies have identified drugs on the World Health Organization's (''WHO'') Model List of Essential Drugs (Medicines) (''MLEM'') have a low prevalence of patent exclusivity. [12] MLEM medicines are those satisfying priority health care needs and are selected on the basis of disease prevalence, safety, efficacy, and comparative cost-effectiveness. [13, 14] Yet, conversely, other studies have reported that certain essential medicines used to treat chronic diseases in LMICs may have limited availability and affordability, especially in public sector settings. [6] [7] [8] Specifically, studies have identified essential medicines treating diabetes, asthma, cardiovascular disease, and cancer as lacking availability and affordability. [15] [16] [17] [18] .
Hence, given rising prevalence of NCDs and urgent need for equitable access, we examined the state of patent and/or exclusivity for identified MLEM NCD medicines for supply-side factors associated with generic production and subsequent availability and affordability. This included determining if identified MLEM NCD medicines had patent or exclusivity protections that could preclude use of active pharmaceutical ingredient (API), MLEM-indicated formulation, or MLEMindicated dosage by generic manufacturers.
Methods

Overview
In general, we employed a two-phase approach to identify then analyze current MLEM NCD medications. In Phase I we began by identifying MLEM medicines treating diabetes, cancers, cardiovascular diseases, and respiratory diseases (''Targeted NCD Medicines''). These NCDs are major contributors to global disease burden and mortality. [1, 2, 6, 8, 19 ] In Phase II, we then examined the patent and exclusivity status of Targeted NCD Medicines using the FDA Approved Medicine Products with Therapeutic Equivalence Evaluation (''Orange Book'') and U.S. Patent and Trademark Office (''USPTO'') databases. The USA system was chosen for patent/exclusivity analysis as it is the largest pharmaceutical market globally, has easily accessible drug exclusivity and patent data sources (e.g., Orange Book), and is likely to have the greatest level of drug IPR protections. [20] .
Phase I: Identifying Targeted NCD Medicines on MLEM
Specifically, to identify Targeted NCD Medicines, we used WHO data sources, i.e., current MLEM (17 th list) and WHO Essential Medicines Library. Currently, MLEM includes over 350 medicines and is updated every 2 years using evidence-based decision processes. [13] The MLEM is divided into two separate categories including ''core'' list medicines representing the minimum medicine needs for basic health systems, and a ''complementary'' list of essential medicines that may be less cost-effective or require diagnostic or monitoring facilities. [13, 14] Since 2002, cost-effectiveness comparisons are conducted but cost or affordability is no longer a reason for MLEM exclusion, nor is patent status of a medicine. [14] The MLEM, although not comprehensive, serves as an initial model list for countries in developing their own national formularies or policy. [14, 21] .
Targeted NCD Medicines were identified by reviewing the most recently revised MLEM and searching for therapeutic subclasses (e.g., ''cardiovascular medicines'') to determine if a drug addresses a targeted NCD. After identification of relevant subclass of drugs from MLEM, we used the WHO Essential Medicines Library to review all identified medicines for the ''disease indication'' to assess if the medicine was specifically indicated for a targeted NCD (note ''disease indication'' is not listed on the MLEM). Based on these results, a ''Final NCD List'' (see Table 1 ) was compiled for further review of associated patent/exclusivity data.
Phase II: Assessing Patent/Exclusivity Status of Targeted NCD Medicines
Once the Final NCD List was compiled, we then analyzed the patent/exclusivity status of these medicines using the FDA Orange Book, which lists all medicine products approved under a New Drug Application (NDAs) (for innovator products) or an Abbreviated New Medicine Application (ANDAs) (for generic products). Patent/exclusivity disclosure contained in the Orange Book are made part of applications submitted by manufacturers to FDA during the NDA or ANDA process. [22] .
FDA-granted exclusive data and marketing rights are also reported in the Orange Book. Exclusivity differs from patent protection in that it provides statutory exclusion of others from marketing or use of originator's test data for subsequent drug applications. Exclusivity terms can run concurrently or in seriatim. [23] USA exclusivity includes data exclusivity for New Chemical Entities or new active moiety (5-years), and marketing exclusivity for Orphan Drug Exclusivity (''ODE'') (7-years), Pediatric Exclusivity (6-months), Patent Challenge Exclusivity (180-days), and changes and submission of supplemental applications (e.g., new uses/indications for already approved products) (3-years). [23] We cross-referenced the API of identified NCD Targeted Medicines with the Orange Book for any patents/exclusivity designation associated with the medication. We then reviewed the relevant drug authorizations for patents/exclusivity designation in MLEM-indicated: (a) API; (b) dosage; and (c) route of administration.
Targeted NCD Medicines were not included as being protected by patent/exclusivity terms if they: (i) had different administration method from that in the MLEM; (ii) were not listed as a reference listed drug; (iii) were classified as having therapeutic equivalence; or (iv) did not make a drug substance claim (''Orange Book Exclusion Criteria''). We did not include drugs with these characteristics because not having the same MLEM-listed administration indicates a different method of administration or formulation than that recommended under the MLEM; a drug not listed as a reference listed drug indicates it is generally not an innovator product (i.e., it is a generic or other formulation); therapeutic equivalence designation indicates these drugs are pharmaceutical equivalents (contain the same active ingredient(s); dosage form and route of administration; and strength, again, a generic); and not making a drug substance claim indicates that the drug does not make a claim on the API. [22] .
For Targeted NCD Medicines with drug applications indicating patent/exclusivity protection not meeting the above Orange Book Exclusion Criteria, we used the USPTO comprehensive database of USA-filed patents through its Patent Application Information (''PAIR'') system to specifically examine applicable patent claims to assess if they were associated with generic production of the API, MLEM indicated route of administration, and MLEM dosage. Here, we did not include patents/exclusivity making claims for (a) an administration or indication not addressed in MLEM; (b) combination products of several drugs/active substances; (c) method patents to manufacturer/process drugs; (d) derivatives, formulations, or compositions containing active substances but not associated with resultant generic production of API; (e) limited exclusivity designation such as Orphan Drug status; and (f) patents for mechanical delivery devices (''USPTO Exclusion Criteria''). This step revalidated the Orange Book Exclusion Criteria and allowed us to look at patent/exclusivity designations that were unclear or that indicated possible protection per Orange Book data.
Our decision algorithm for inclusion/exclusion criteria is provided in Figure 1 . A summary of the Orange Book and USPTO Exclusion Criteria and examples of their application is provided in Table 2 . Searches and analysis were conducted from June -August 2011.
Results
Phase I MLEM NCD List Results
Phase I showed close to one-quarter, 22% (79/359) of all medicines on MLEM are used to treat a targeted NCD. Cancer and cardiovascular diseases make up the bulk of Targeted NCD Medicines addressed by MLEM ( Table 3) .
Phase II Patent/Exclusivity Results
In Phase II, initial Orange Book patent searches on the 79 medicines in the Final NCD List showed only 42% (33) of these medicines had some type of positive results for patent and exclusivity protection, 43% (34) in negative results (i.e., no patent exclusivity of any type), 10% (8) which were not covered by the Orange Book (i.e., certain biologics, dialysis solutions, and insulin), and 5% (4) with no information available.
Using these results, we assessed all associated patent and exclusivity terms of the 33 Targeted NCD Medicines with positive results. Of these 33 identified Targeted NCD Medicines, only 8 had at least one patent/exclusivity term that did not meet the Orange Book Exclusion criteria.
These 8 remaining drugs then were assessed using patent/ exclusivity data from USPTO data sources. These included calcium folinate (in USA: leucovorin), doxorubicin, amlodipine, hydrochlorothiazide, simvastatin, metformin, budesonide, and salbutamol (in USA: albuterol). Applying our USPTO Exclusion Criteria, we found that none of these drugs had patent claims that would impede generic manufacture of API, nor the MLEMindicated route of administration or dosage ( Table 4) . Generic versions of drugs containing the API for all 8 of these drugs are commercially available.
However, upon careful examination of patent claims for these 8 drugs, we found that two respiratory medications, salbutamol and budesonide, have patent/exclusivity data for MLEM-indicated formulation/administration via inhalers and their related administration technology that may impede generic availability. Yet, this IPR protection may be an artifact of USA prohibition of inhalers containing chlorofluorocarbons (''CFCs''), scheduled to be phased out of use due to negative environmental impact. [24] Due to the prohibition of CFC inhalers, the FDA has recommended use of hydrofluoroalkane (''HFA'') propellants. [24] Yet, no generic forms of HFA propellants are available for salbutamol, and, similarly, patents may also affect availability of HFA administration and delivery devices of budesonide. These findings illustrate the complexity and dynamic nature of IPR provisions that may impede generic production that can result in lack of availability or affordability of essential NCD medications.
Discussion
We found that none of the Targeted NCD Medicines have applicable patent/exclusivity provisions that could hinder possible generic production of the API or MLEM-indicated formulation or dosage in our study. This implies, if these results are generalizable, that availability, affordability and delivery of essential NCD medicines, particularly in LMICs where studies have already identified access limitations, may be affected by other and/or additional considerations. With literally no WHO MLEM-based NCD drugs under our criteria being subject to API, dosage, or administration patent and/or exclusivity provisions, generic production and subsequent affordability of NCD drugs appears not to be solely an IPR issue. Hence, strategies to improve generic availability to NCD essential medicines must take into account other factors associated with medicines access that have been previously identified. [25] [26] [27] [28] . Such strategies should include assessment using a comprehensive definition of ''access'' including concurrent definitions of physical availability, affordability, geographic accessibility and acceptability that affect both the supply and demand considerations, which are beyond the scope of this paper. [29, 30] While in this paper we limit our findings to and use of the term ''access'' to a narrow working definition of supply-side factors of availability and affordability influenced by generic production, indeed, several additional factors may limit greater NCD drug access, production and uptake. These include demand-side aspects of availability including prescribing practices, lack of generic substitution/ procurement, acceptability of medicines for prescribers and users, greater public and private sector health financing, and better utilization of available medications. [6, 8, 18, [31] [32] [33] .
In the scope of factors associated with IPRs, combination therapies that include multiple active substances may also be clinically efficacious, though are not covered under patent exclusivity for a single NCD Medicine active substance or the MLEM. This includes the suggested use of polypills (a combination drug with multiple API) for the prevention of cardiovascular disease that has been shown to be potentially clinically beneficial. [34] Though use of polypills may reduce cost and increase availability if API is off-patent, they may also be subject to patent protection for the formulation or may not otherwise be commercially attractive for manufacturers. [35] In addition, methods of administration (such as lozingers, aerosol formulations, pen injectors, etc.) that can have better uptake in certain patient populations may also be subject to patent protection and not covered in the MLEM.
Also, as in the case of calcium folinate and metformin, even if a medicine is no longer under patent protection, there may be lack of sufficient generic or off-patent brand name manufacturing capacity or incentives to meet clinical needs. In these cases, factors (such as low reimbursement as a result of private and public policies) may have an effect on production and investment in manufacturing and export for these essential drugs, leading to shortages. [36, 37] This is especially worrisome given studies reporting significantly lower availability of chronic disease medications in public sector settings and high-costs in the private sector for LMICs. [6, 8] Consequentially this creates a dual burden of limited availability at the public level (which may provide more affordability or free access), and lack of affordability at the private level for patients who are already predominantly paying out-ofpocket and are resource-constrained.
It should also be noted that the MLEM is not meant to be a comprehensive list of all medications necessary to address the plethora of debilitating conditions NCDs pose and their accompanying complex and ongoing treatment regimes. [7, 21] Indeed, outside of the MLEM, there may be other NCD drugs that are clinical efficacious but are not included on it. This includes a number of new medicines for the treatment of cancer that have been identified as being excluded from the MLEM. [38] .
In addition, given both developing and developed country needs for a full suite of NCD drugs, the ''patent cliff'', which represents dates when blockbuster drug patents/exclusivity for innovator drugs terminate, may present generic manufacturing opportunities and the chance to more proactively assess inclusion of therapies transitioning in cost-effectiveness for the MLEM. [39] Indeed, these pharmaceuticals that are coming offpatent will likely experience rapid, significant price reductions from generic production. [40] MLEM inclusion for these products could aid in providing technical assistance and expedite selection and inclusion on national drug formularies by alerting member states to the availability of lower-cost generic versions that would subsequently make these treatments more cost-effective and affordable.
To promote these potential benefits, WHO may wish to revisit the MLEM review process to more proactively assess if these NCD products coming off-patent adequately meet the criteria for safety, efficacy, and increased comparative cost-effectiveness outlined in the MLEM. Efforts should be made to actively engage generic manufacturers to address the need for these medications in underserved markets increasingly suffering from a growing burden of NCDs. These efforts could also extend to more active promotion of local manufacturing of essential NCD medicines to potentially increase economic benefits, availability, and achieve cost reduction. [6, 41, 42] .
Further, potential expansion of the MLEM complimentary list to incorporate this proactive review of NCD medicines with expiring patent/exclusivity protection, may be a potential method to identify and encourage generic manufacturers and national drug formularies to develop, list, and invest in these products. These efforts would create a more dynamic MLEM, and potentially enable speedier access to needed medicines if they were appropriately deemed ''essential.''
Study Limitations
It is important to note that the WHO MLEM represents only a portion of medicines available for the effective treatment of NCDs, and other strategic medical approaches may be necessary for efficacious clinical treatment and therefore may not be included on this list. Further, national drug formularies and established standard of care provisions or clinical practice guidelines for medical professionals may differ from those medicines recommended in the MLEM. In addition, a small subset of Targeted NCD Medicines on the MLEM were not assessed or did not have assessable information. The reasons for this includes: (a) medicine is a metabolite or intermediary; (b) biologic product which were not assessed for patentability/exclusivity; (c) general health product (such as insulin, human normal immunoglobulin) not covered under patent protection; or (d) substance/ingredient used in manufacturer/process of medicine, but not listed in Orange Book. However, these represented only 5% of all identified Targeted NCD Medicines.
In addition, we only assessed patent status of identified NCD Medicines using the FDA Orange Book, which limits the scope of our analysis to the USA. However, these results would tend to be overinclusive in IPRs due to securing rights in the globe's largest drug market would generally be a priority for pharmaceutical manufacturers.
It should also be noted that this study methodology did not survey non-public databases for drug patent/exclusivity information and is limited to the USA. We also did not specifically assess the family patent status of NCD medicines. This includes determining from the family of patents the applicable base patent (the earliest patent for the API) and any API supplementary or ancillary patents. We limited our searches to Orange Book data and publicly accessible databases. However, if a base patent had remaining patent or exclusivity terms it should be disclosed in the Orange Book. If the base patent was expired, then it should not appear in these search results. For future study, detailed examination of the patent family for all Targeted NCD Medicines may provide further insights.
In addition, our data sources have certain limitations. It is possible patent rights registered and afforded in the Orange Book may not be recognized by other sovereignties. There may also be errors in the Orange book, e.g., API may or may not be registered or approved or may or may not be afforded additional patent protection. Hence, the population of drugs included in this study may reflect these errors as well, although the Orange Book is the standard source for USA-based IPR information. In addition, patent information reported in the Orange Book is based on NDA and ANDA applications and is not validated by the FDA. Though applicants must attest the information contained in an application is accurate, the FDA does not have a process to remove such information if it is inaccurate. Disputes can be filed with the FDA regarding inaccurate patent information, but it is ultimately the responsibility of the applicant to withdraw or amend patent information. Generally, the FDA relies on the patent litigation system to adjudicate these kinds of disputes.
Concluding Remarks
It has been 8 years and four rounds of updates to the MLEM since Attaran's pioneering study reported that only a few essential medicines are patented. The results from this study show that little has changed in relation to patents/exclusivity status for the specific subclasses of essential medicines needed to treat NCDs. This study provides important preliminary data on the association of patents/ exclusivity for generic production, availability and affordability of NCD essential medicines; however, further research is necessary. These efforts should include examination of converging mutual benefits from strategies of IPR management, critical assessment of non IPR-factors that may impede availability and affordability, and possible reexamination of the process of review/update of the MLEM. [25] Finally, global health policy solutions should be directed towards a comprehensive menu of evidence-based interventions and improved global governance to improve access to medicines, while also identifying and adequately addressing the multitude of barriers to global health progress in the control of NCDs.
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